The short version of albumin conjugate fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-12. Anything still debated is marked as such rather than presented as settled.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Many complexes are known with cyclopropenium ligands. Examples include [M(C3Ph3)(PPh3)2]+ (M = Ni, Pd, Pt) and Co(C3Ph3)(CO)3. Such compounds are prepared by reaction of cyclopropenium salts with low valent metal complexes.
== Signs and symptoms == Acrocyanosis is characterized by peripheral cyanosis: persistent cyanosis of the hands, feet, knees, or face. The extremities often are cold and clammy and may exhibit some swelling (especially in warmer weather). The palms and soles exhibit a wide range of sweating from moderately moist to profuse, but all peripheral pulses should have normal rate, rhythm, and quality. Exposure to cold temperatures worsens the cyanosis, while it often improves on warming. Aside from the color changes, patients normally are asymptomatic and therefore there is usually no associated pain. The most common sign, discoloration, usually is what prompts patients to seek medical care.
Imidazole and its derivatives have high affinity for metal cations. One of the applications of imidazole is in the purification of His-tagged proteins in immobilised metal affinity chromatography (IMAC). Imidazole is used to elute tagged proteins bound to nickel ions attached to the surface of beads in the chromatography column. An excess of imidazole is passed through the column, which displaces the His-tag from nickel coordination, freeing the His-tagged proteins.
Sources: en.wikipedia.org
Nausea: ~ 8%; 1% severe nausea and 1% discontinued treatment due to nausea. Diarrhea: ~ 7%; <1% of patients had severe diarrhea and <1% of patients discontinued treatment due to diarrhea. Less common adverse reactions: <1% A 2018 pooled analysis from three phase III, randomized, double-blind, placebo-controlled studies on usage for Opioid-Induced Constipation, found that the numbers of patients reporting adverse effects were similar in both the lubiprostone and placebo treatment groups for all opioid classes (P ≥ 0.125); however, gastrointestinal adverse effects were reported more frequently by those receiving lubiprostone than 2 of the 3 opioid groups. The most commonly reported TEAEs in the lubiprostone treatment groups were nausea (13.4%–18.1%), diarrhea (1.2%–13.9%), and abdominal pain (4.7%–5.6%). In the population overall, the greatest likelihood of experiencing the first episode of any of these three TEAEs was greatest in the first week of treatment and decreased thereafter. According to Medscape, the most common (>10%) were: Nausea, Diarrhea (7-12%), Headache (2-11%). Less common side effects (1-10%) included: Abdominal pain (4-8%), Abdominal distension (3-6%), Flatulence (4-6%), Vomiting (3%), Loose stools (3%), Edema (1-3%), Abdominal discomfort (1-3%), Dizziness (3%), Chest discomfort/pain (2%), Dyspnea (2%), Dyspepsia (2%), Fatigue (2%), Dry mouth (1%).
Use of oxytocin has been found to significantly shorten labor duration. Early oxytocin augmentation has also been found to increase the probability of spontaneous vaginal delivery and reduce the risk of chorioamnionitis or intrauterine infection. Since a landmark investigation was published in JAMA Pediatrics by researchers in 2013, the potential link between oxytocin use during childbirth and increased risks of Autism Spectrum Disorder (ASD) in children's development has been a topic of debate. There is no robust evidence in support of oxytocin causing ASD or other neurodevelopmental disorders. Oxytocin was added to the Institute for Safe Medication Practices's list of High Alert Medications in Acute Care Settings in 2012. The list includes medications that have a high risk for harm if administered incorrectly. During pregnancy, increased uterine motility has led to decreased heart rate, cardiac arrhythmia, seizures, brain damage, and death in the fetus or neonate. Increased uterine motility is a hallmark of both spontaneous labor and induced labor, therefore the risks associated with uterine motility are not specific to this medication. Use is linked to an increased risk of postpartum depression in the mother. Certain learning and memory functions are impaired by centrally administered oxytocin. Also, systemic oxytocin administration can impair memory retrieval in certain aversive memory tasks. However, oxytocin does seem to facilitate learning and memory specifically for social information.
hydrophilic Soluble in or having an affinity for water or other polar compounds; describing a polar molecule, or a moiety or functional group within a molecule, which participates in intermolecular interactions such as hydrogen bonding with other polar molecules and therefore readily dissolves in polar solvents such as water or aqueous solutions. Unlike hydrophobic compounds, hydrophilic compounds can form energetically favorable contacts with the aqueous phase of biological fluids and so can often be suspended directly in the cytosol or exposed to extracellular spaces. Together, the contrasting properties of hydrophilicity and hydrophobicity play major roles in determining the structural conformations and functions of most biomolecules.
Sources: en.wikipedia.org
== Research and career == In 1975, Theo Wallimann completed his Ph.D. Dissertation on “M-line-bound Creatine Kinase and Myofibrillar Structure” in the laboratory of Prof. Hans M. Eppenberger at the Institute of Cell Biology at ETH Zurich with distinction and received the ETH prize and medal. From 1975 - 1981, Wallimann worked as a post-doctoral research associate with Andrew G. Szent-Györgyi , at the Biology Department of Brandeis University on the subject of "Myosin-linked calcium regulation of muscle contraction". After rejoining the Biology Dept of the ETH-Zurich in 1981, Wallimann became a Lecturer in 1984 with his Habilitation on: "Localization and function of M-line-bound creatine kinase: M-band model and Phospho-Creatine Shuttle"). In 1994, Wallimann was awarded the title of Professor and in the next two years he became Head and Deputy Head of the Institute of Cell Biology. Wallimann resigned from his post in June 2008 and is now Emeritus and member of the ETH Alumni organisation. In 2005, Wallimann was awarded with the Alfred-Vogt-Prize in 2005 and in 2023, 2024 and 2025 he received the Research.com Recognition Leader Award for Biology and Biochemistry in Switzerland. In 2025, Theo Wallimann has been honored by the International Society of Sports Nutrition with a “Life-time Achievement Award” for his research on the «Creatine Kinase System and Creatine», at the Internatl. Congress on «Creatine for Health», held during March 12th-16th 2025 in Munich, Germany: https://creatineforhealth.com/creatine-conference-2025/
A football pitch, or field, can be used as a man-in-the-street unit of area. The standard FIFA football pitch for international matches is 105 m (344 ft) long by 68 m (223 ft) wide (7,140 m2 or 0.714 ha or 1.76 acres); FIFA allows for a variance of up to 5 m (16.4 ft) in length in either direction and 7 m (23.0 ft) more or 4 m (13.1 ft) less in width (and larger departures if the pitch is not used for international competition), which generally results in the association football pitch generally only being used for order of magnitude comparisons. An American football field, including both end zones, is 360 by 160 ft (120.0 by 53.3 yd; 109.7 by 48.8 m), or 57,600 square feet (5,350 m2) (0.535 hectares or 1.32 acres). A Canadian football field is 65 yards (59 m) wide and 110 yards (100 m) long with end zones adding a combined 40 yards (37 m) to the length, making it 87,750 square feet (8,152 m2) or 0.8215 ha (2.030 acres). An Australian rules football field may be approximately 150 metres (160 yd) (or more) long goal to goal and 135 metres (148 yd) (or more) wide, although the field's elliptical nature reduces its area to a certain extent. A 150-by-135-metre (164 by 148 yd) football field has an area of approximately 15,900 m2 (1.59 ha; 3.9 acres), twice the area of a Canadian football field and three times that of an American football field.
=== SNP microarrays === In high-density oligonucleotide SNP arrays, hundreds of thousands of probes are arrayed on a small chip, allowing for many SNPs to be interrogated simultaneously. Because SNP alleles only differ in one nucleotide and because it is difficult to achieve optimal hybridization conditions for all probes on the array, the target DNA has the potential to hybridize to mismatched probes. This is addressed somewhat by using several redundant probes to interrogate each SNP. Probes are designed to have the SNP site in several different locations as well as containing mismatches to the SNP allele. By comparing the differential amount of hybridization of the target DNA to each of these redundant probes, it is possible to determine specific homozygous and heterozygous alleles. Although oligonucleotide microarrays have a comparatively lower specificity and sensitivity, the scale of SNPs that can be interrogated is a major benefit. The Affymetrix Human SNP 5.0 GeneChip performs a genome-wide assay that can genotype over 500,000 human SNPs.
The proposed plan would reduce commuter bus services and lines, delay the state's transition to electric buses, and cancel plans to expand the Brunswick Line. He later announced a one-year infusion of $150 million to the state's transportation fund, with most of the added funding being used to restore highway user revenue funding, to ease the effects of the cuts. Although the legislature included provisions to raise fees on vehicle registration for electric vehicles and heavier cars to prevent drastic cuts to the state's transportation projects, the Moore administration again proposed $1.3 billion in cuts to Maryland's transportation budget in September 2024, which would delay various infrastructure projects around the state, including the widening of the American Legion Memorial Bridge and the state's transition to electric buses. The proposed cuts would have also put the Maryland Transit Administration at risk of losing a federal grant that would have allowed it to replace the Baltimore LightRail's fleet of trains; however, this was avoided after Moore proposed about $420 million in vehicle-related fee increases in his fiscal year 2026 budget. In September 2025, the Moore administration proposed a $300 million funding increase for transportation projects in Maryland. In October 2024, Moore said he supported the widening of Interstate 81 in Maryland.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.